Pulmonary ComplicationNCT06173583

ARISCAT and LAS VEGUS Risk Scores for Predicting Postoperative Pulmonary Complications After Cardiac Surgery

An observational study of Pulmonary Complication and Postoperative Complications, run by Aga Khan University at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The goal of this observational study is to compare the, ARISCAT and LAS VEGUS scales, for predicting postoperative pulmonary complications in patients undergoing cardiac surgery. The study aims to compare the diagnostic accuracies of the two risk prediction scores in predicting postoperative pulmonary complications. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Pulmonary Complication, Postoperative Complications, Postoperative Pulmonary Complications
What is being tested?: Detection/screening
How many people: 181 participants
Where: 1 sitePakistan
Study dates: 14 Feb 2020to 31 Jan 2021
Phase: Observational
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients of either gender, aged between 18-65 years, undergoing elective heart surgery.

Who may be able to join

Patients undergoing elective heart surgery

Who cannot join

Refusal to consent
Patients undergoing emergency surgery

Trial locations and contacts

1 site in 1 country.

Pakistan1 site

Aga Khan University Hospital
Karachi, Sindh, 74800

Other trials in Pakistan

About this study

Conditions: Pulmonary Complication, Postoperative Complications, Postoperative Pulmonary Complications
Being tested: Detection/screening
Medical subject headings: Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Detection/screeningDiagnostic test
Using ARISCAT and LAS VEGUS risk scores for predicting PPCs

Study groups in NCT06173583
Study group	Role	What they receive
Adult In-patient Cardiac surgery		Adult patients undergoing elective open-heart surgery Receives: Diagnostic Test: Detection/screening

What is being measured

The primary outcome is the main question the study is designed to answer.

Diagnostic Accuracy of ARISCAT and LAS VEGAS Scoring systems
Diagnostic Accuracy to judge the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) and Local Assessment of Ventilatory Management During General Anaesthesia for Surgery (LAS VEGAS) Scoring systems to predict Postoperative Pulmonary Complications (PPC) after Cardiac surgery. Scores, ARISCAT ≥ 27 and LAS VEGAS ≥ 8 were determined for PPCs.
Measured: Day 1-5

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

14 Feb 202031 Jan 2021

First posted15 Dec 2023
Study start14 Feb 2020
Primary completion31 Jan 2021
Study completion31 Jan 2021

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Pulmonary ComplicationStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Cohort
Time perspective: Prospective
Enrolment: 181 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06173583
Sponsor's protocol ID: 2020-1743-8434
Status last verified: Feb 2024
First submitted: 8 Dec 2023
Last updated: 14 Feb 2024
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
RecruitingPhase 1
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Mesothelioma, Neoplasms

All Pulmonary Complication trials

Study at a glance

From the registry record, last updated by the sponsor on 14 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: ARISCAT and LAS VEGUS Risk Scores for Predicting Postoperative Pulmonary Complications After Cardiac Surgery
ClinicalTrials.gov ID: NCT06173583
Acronym / sponsor ID: 2020-1743-8434
Conditions: Pulmonary Complication, Postoperative Complications, Postoperative Pulmonary Complications
Study type: Observational
Recruitment status: Completed
Enrolment: 181 participants (actual)
Lead sponsor: Aga Khan UniversityUniversity, hospital or other
Study start: 14 Feb 2020 (actual)
Primary completion: 31 Jan 2021 (actual)
Study completion: 31 Jan 2021 (actual)
First posted: 15 Dec 2023 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model: Cohort
Time perspective: Prospective
Number of arms: 1

Arm	Type	Receives
Adult In-patient Cardiac surgery	–	Diagnostic Test: Detection/screeningAdult patients undergoing elective open-heart surgery

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult
Study population: Patients of either gender, aged between 18-65 years, undergoing elective heart surgery.

Key inclusion criteria (1 listed)

Patients undergoing elective heart surgery

Key exclusion criteria (2 listed)

Refusal to consent
Patients undergoing emergency surgery

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Detection/screeningUsing ARISCAT and LAS VEGUS risk scores for predicting PPCs	Diagnostic test	Adult In-patient Cardiac surgery

Primary outcome

Diagnostic Accuracy of ARISCAT and LAS VEGAS Scoring systems
Time frame: Day 1-5
Diagnostic Accuracy to judge the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) and Local Assessment of Ventilatory Management During General Anaesthesia for Surgery (LAS VEGAS) Scoring systems to predict Postoperative Pulmonary Complications (PPC) after Cardiac surgery. Scores, ARISCAT ≥ 27 and LAS VEGAS ≥ 8 were determined for PPCs.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2024.

Related trials for Pulmonary Complication

RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Recruiting
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Premature Infants, Bronchopulmonary Dysplasia
RecruitingPhase 1
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Mesothelioma, Neoplasms

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Pulmonary Complication and Postoperative Complications, run by Aga Khan University at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic Accuracy of ARISCAT and LAS VEGAS Scoring systems (time frame: Day 1-5). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06173583.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2024.